Characterization and mutagenesis of Gal/GlcNAc-6-O-sulfotransferases

被引:11
作者
Grunwell, JR
Rath, VL
Rasmussen, J
Cabrilo, Z
Bertozzi, CR [1 ]
机构
[1] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA
[2] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA
[3] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA
[4] Thios Pharmaceut Inc, Emeryville, CA 94608 USA
关键词
D O I
10.1021/bi0269557
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The installation of sulfate groups on the carbohydrate residues of glycoproteins, glycolipids, and glycosaminoglycans is a critical posttranslational modification that occurs in all higher eukaryotes. The Gal/GalNAc/GlcNAc-6-O-sulfotransferases (GSTs) are a recently discovered family of carbohydrate sulfotransferases that share significant sequence homology at the amino acid level and mediate a number of different biological processes such as leukocyte adhesion at sites of chronic inflammation. Structural and mechanistic studies of this family of sulfotransferases have been hindered by the lack of a productive recombinant protein expression system. We developed a baculovirus expression system for five of the seven cloned GSTs and determined their kinetic parameters using both thin-layer chromatography and a recently developed polymer dot-blot assay. We used these tools to perform the first site-directed mutagenesis study of a member of this sulfotransferase family, GST2. Using sequence alignments with other carbohydrate and cytosolic sulfotransferases, we selected residues within the putative binding regions for 3'-phosphoadenosine 5'-phosphosulfate (PAPS) and the carbohydrate substrate for mutagenesis. Kinetic analysis of the mutants identified residues that are essential for catalytic activity. These results should facilitate mechanistic studies and the development of small molecule inhibitors of this enzyme family to ameliorate chronic inflammatory diseases.
引用
收藏
页码:15590 / 15600
页数:11
相关论文
共 94 条
[1]   Macular corneal dystrophy type I and type II are caused by distinct mutations in a new sulphotransferase gene [J].
Akama, TO ;
Nishida, K ;
Nakayama, J ;
Watanabe, H ;
Ozaki, K ;
Nakamura, T ;
Dota, A ;
Kawasaki, S ;
Inoue, Y ;
Maeda, N ;
Yamamoto, S ;
Fujiwara, T ;
Thonar, EJMA ;
Shimomura, Y ;
Kinoshita, S ;
Tanigami, A ;
Fukuda, MN .
NATURE GENETICS, 2000, 26 (02) :237-241
[2]   Human corneal GlcNAc 6-O-sulfotransferase and mouse intestinal GlcNAc 6-O-sulfotransferase both produce keratan sulfate [J].
Akama, TO ;
Nakayama, J ;
Nishida, K ;
Hiraoka, N ;
Suzuki, M ;
McAuliffe, J ;
Hindsgaul, O ;
Fukuda, M ;
Fukuda, MN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16271-16278
[3]   Synthesis and anticoagulant activity of sulfated glucoside-bearing polymer [J].
Akashi, M ;
Sakamoto, N ;
Suzuki, K ;
Kishida, A .
BIOCONJUGATE CHEMISTRY, 1996, 7 (04) :393-395
[4]  
AlvarezDominguez C, 1997, INFECT IMMUN, V65, P78
[5]   Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase [J].
Anderson, JAM ;
Fredenburgh, JC ;
Stafford, AR ;
Guo, YS ;
Hirsh, J ;
Ghazarossian, V ;
Weitz, JI .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :9755-9761
[6]  
Armstrong J I, 2000, Curr Opin Drug Discov Devel, V3, P502
[7]   REGARDING THE GLYCOPROTEIN HORMONES AND THEIR SULFATED OLIGOSACCHARIDES [J].
BAENZIGER, JU .
GLYCOBIOLOGY, 1995, 5 (05) :459-459
[8]   Influence of sulfation on platelet aggregation and activation with differentially sulfated hyaluronic acids [J].
Barbucci, R ;
Lamponi, S ;
Magnani, A ;
Poletti, LF ;
Rhodes, NP ;
Sobel, M ;
Williams, DF .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 1998, 6 (02) :109-115
[9]  
BARNES S, 1986, J LIPID RES, V27, P1111
[10]   Sulfation of endothelial mucin by corneal keratan N-acetylglucosamine 6-O-sulfotransferase (GST-4β) [J].
Bartes, A ;
Bhakta, S ;
Hemmerich, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 282 (04) :928-933